talipexole has been researched along with 1-methyl-4-phenylpyridinium in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitamura, Y; Kohno, Y; Nakazawa, M; Nomura, Y | 1 |
| Kakimura, JI; Kitamura, Y; Kohno, Y; Kosaka, T; Matsuoka, Y; Nomura, Y; Taniguchi, T | 1 |
| Kakimura, J; Kitamura, Y; Kohno, Y; Nomura, Y; Takata, K; Taniguchi, T | 1 |
| Matsubara, K; Ohtaki, K; Shimizu, K; Shiono, H | 1 |
4 other study(ies) available for talipexole and 1-methyl-4-phenylpyridinium
| Article | Year |
|---|---|
Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Azepines; Benzothiazoles; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Homovanillic Acid; In Vitro Techniques; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neostriatum; Pramipexole; Synaptosomes; Thiazoles | 1997 |
Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Antiparkinson Agents; Apoptosis; Azepines; Benzothiazoles; Bromocriptine; Bucladesine; Caspase 3; Caspases; Dopamine Agonists; Humans; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Antiparkinson Agents; Azepines; Benzothiazoles; Caspases; Cell-Free System; Cytochrome c Group; Cytosol; Deoxyadenine Nucleotides; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Nerve Tissue Proteins; Organelles; Pramipexole; Synucleins; Thiazoles; Tumor Cells, Cultured | 2001 |
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Animals; Animals, Newborn; Azepines; Cabergoline; Caspases; Cell Count; Cycloheximide; Dizocilpine Maleate; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ergolines; Excitatory Amino Acid Antagonists; Herbicides; Immunohistochemistry; Mesencephalon; NADPH Dehydrogenase; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Organ Culture Techniques; Paraquat; Piperazines; Protein Synthesis Inhibitors; Quinoxalines; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2003 |